News

Unique psoriatic arthritis genetic risk loci discovered


 

References

Several genetic risk loci unique to psoriatic arthritis have been identified in a study of samples from 1,962 patients with the disease and 8,923 healthy population controls of white ancestry, according to Dr. John Bowes and his associates.

The investigators used Immunochip genotyping array to fine map previously reported immune-related susceptibility loci, including known psoriasis susceptibility loci, to identify novel psoriatic arthritis (PsA) susceptibility loci.

They found a risk locus specific to PsA at chromosome 5q31, and they detected PsA risk variants at chromosome 1q31, a known psoriasis susceptibility locus. They found independent associations between PsA and three human leukocyte antigen (HLA) genes as well as three non-HLA loci. Finally, they determined that the PsA genetic risk variants preferentially associated with epigenetic markers of open chromatin in CD8+ memory primary T cells, supporting “their importance in the underlying disease mechanism.”

Until this point, the majority of risk loci associated with PsA were shared with psoriasis, but the discovery of unique risk loci could begin to explain fundamental differences between psoriasis and PsA, the investigators said.

Read the full study published Feb. 5 in Nature Communications (doi:10.1038/ncomms7046).

Recommended Reading

Case series: Ustekinumab for psoriasis helps skin, hurts joints
MDedge Rheumatology
Early psoriatic arthritis treatment with etanercept gives better outcomes
MDedge Rheumatology
Psoriasis treatment recommendations address four clinical scenarios
MDedge Rheumatology
Secukinumab earns FDA approval for plaque psoriasis
MDedge Rheumatology
Corticosteroid spray quickly, safely relieves psoriasis scaling
MDedge Rheumatology
Consider Chikungunya virus in new-onset polyarthritis
MDedge Rheumatology
Joint mechanical stress: A psoriatic arthritis trigger in genetically susceptible individuals?
MDedge Rheumatology
Survey: Psoriasis/psoriatic arthritis undertreated
MDedge Rheumatology
Most cost-effective psoriasis treatment: methotrexate
MDedge Rheumatology
Methotrexate coverage woes
MDedge Rheumatology